Revision 1

#13347 Store at -20C

FABP7 (D8N3N) Rabbit mAb

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355) orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
WB, IF-IC	H R	Endogenous	15	Rabbit IgG	#O15540	2173

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunofluorescence (Immunocytochemistry)	1:2000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

FABP7 (D8N3N) Rabbit mAb recognizes endogenous levels of total FABP7 protein. Species cross-reactivity for IF-IC is human only.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val84 of human FABP7 protein.

Background

Fatty acid binding proteins (FABPs) bind to fatty acids and other lipids to function as cytoplasmic lipid chaperones (1). They participate in the transport of fatty acids and other lipids to various cellular pathways (2). Differential expression of FABPs is found in several types of tumors and their normal-cell counterparts (3). FABP7 is abundantly expressed in fetal brain and may be essential for development (4). Expression is required for the establishment of the radial glial fiber system, a system that is necessary for the development of cortical layers (5). Increased expression of FABP7 is associated with reduced survival in patients with glioblastoma (6), and is also found in glial cells following nerve injury (7). Investigators have found loss of FABP7 may be involved in the development and progression of breast cancer and expression of FABP7 has been shown to induce mammary differentiation and to inhibit growth of breast cancer cells (8,9).

Background References

1. Storch, J. and Thumser, A.E. (2010) *J Biol Chem* 285, 32679-83.
2. Haunerland, N.H. and Spener, F. (2004) *Prog Lipid Res* 43, 328-49.
3. Khan, S.H. and Sorof, S. (1994) *Proc Natl Acad Sci U S A* 91, 848-52.
4. Shimizu, F. et al. (1997) *Biochim Biophys Acta* 1354, 24-8.
5. Feng, L. and Heintz, N. (1995) *Development* 121, 1719-30.
6. Liang, Y. et al. (2005) *Proc Natl Acad Sci U S A* 102, 5814-9.
7. Miller, S.J. et al. (2003) *Mol Cell Biol* 23, 2213-24.
8. Shi, Y.E. et al. (1997) *Cancer Res* 57, 3084-91.
9. Wang, M. et al. (2000) *Cancer Res* 60, 6482-7.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

WB: Western Blotting **IF-IC:** Immunofluorescence (Immunocytochemistry)

Cross-Reactivity Key

H: human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Mi:** mink **C:** chicken **Dm:** D. melanogaster **X:** Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Sc:** S. cerevisiae **Ce:** C. elegans **Hr:** horse **GP:** Guinea Pig **Rab:** rabbit **All:** all species expected

Trademarks and Patents

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.